

Edgars Jecs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3558155/publications.pdf>

Version: 2024-02-01

11
papers

133
citations

1307594

7
h-index

1281871

11
g-index

12
all docs

12
docs citations

12
times ranked

225
citing authors

#	ARTICLE	IF	CITATIONS
1	Small molecule and peptide-based CXCR4 modulators as therapeutic agents. A patent review for the period from 2010 to 2018. <i>Expert Opinion on Therapeutic Patents</i> , 2020, 30, 87-101.	5.0	32
2	Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 7168-7188.	6.4	22
3	Discovery of Tetrahydroisoquinoline-Containing CXCR4 Antagonists with Improved in Vitro ADMET Properties. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 946-979.	6.4	19
4	Synthesis and SAR of 1,2,3,4-Tetrahydroisoquinoline-Based CXCR4 Antagonists. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 17-22.	2.8	13
5	Synthesis of Novel Tetrahydroisoquinoline CXCR4 Antagonists with Rigidified Side-Chains. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 89-93.	2.8	12
6	Two Ene- π -Yne Metathesis Approaches to the Total Synthesis of Amphidinolide P. <i>Organic Letters</i> , 2015, 17, 3510-3513.	4.6	10
7	Discovery of N-Alkyl Piperazine Side Chain Based CXCR4 Antagonists with Improved Drug-like Properties. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 446-451.	2.8	9
8	Toward the synthesis of amphidinolide P: optimization of a model ene- π -yne metathesis fragment coupling. <i>Tetrahedron Letters</i> , 2014, 55, 4933-4937.	1.4	6
9	Accelerated Discovery of Potent Fusion Inhibitors for Respiratory Syncytial Virus. <i>ACS Infectious Diseases</i> , 2020, 6, 922-929.	3.8	6
10	Amino-Heterocycle Tetrahydroisoquinoline CXCR4 Antagonists with Improved ADME Profiles via Late-Stage Buchwald Couplings. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1605-1612.	2.8	3
11	Synthesis and Evaluation of Novel Tetrahydronaphthyridine CXCR4 Antagonists with Improved Drug-like Profiles. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 4058-4084.	6.4	1